Evaluating the benefit of PBS vs. VMAT dose distributions in terms of dosimetric sparing and robustness against inter-fraction anatomical changes for pediatric abdominal tumors by Guerreiro, Filipa et al.
 
 
 University of Groningen
Evaluating the benefit of PBS vs. VMAT dose distributions in terms of dosimetric sparing and
robustness against inter-fraction anatomical changes for pediatric abdominal tumors
Guerreiro, Filipa; Zachiu, Cornel; Seravalli, Enrica; Ribeiro, Cássia O; Janssens, Geert O;






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Guerreiro, F., Zachiu, C., Seravalli, E., Ribeiro, C. O., Janssens, G. O., Ries, M., de Senneville, B. D.,
Maduro, J. H., Brouwer, C. L., Korevaar, E. W., Knopf, A. C., & Raaymakers, B. W. (2019). Evaluating the
benefit of PBS vs. VMAT dose distributions in terms of dosimetric sparing and robustness against inter-
fraction anatomical changes for pediatric abdominal tumors. Radiotherapy and Oncology, 138, 158-165.
https://doi.org/10.1016/j.radonc.2019.06.025
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Evaluating the benefit of PBS vs. VMAT dose distributions in terms of dosimetric sparing 






























Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands. 
2
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, 
Groningen, The Netherlands. 
3
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.  
4
Princess Máxima Center for Paediatric Oncology, Utrecht, The Netherlands. 
5
Imaging Division, University Medical Center Utrecht, Utrecht, The Netherlands. 
6
Institut de Mathématiques de Bordeaux, University of Bordeaux, Bordeaux, France. 
 
Corresponding Author: Filipa Guerreiro; M.S 
Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands. 





Keywords: pediatric IGRT; pediatric abdominal tumors; robust pencil beam scanning; proton therapy; 















Background and purpose: To evaluate the dosimetric sparing and robustness against inter-fraction 
anatomical changes between photon and proton dose distributions for children with abdominal tumors. 
Material and Methods: Volumetric modulated arc therapy (VMAT) and intensity-modulated pencil beam 
scanning (PBS) proton dose distributions were calculated for 20 abdominal pediatric cases (average 3, 
range 1-8 years). VMAT plans were based on a full-arc while PBS plans on 2-3 posterior-oblique 
irradiation fields. Plans were robustly optimized on a patient-specific internal target volume (ITV) using a 
uniform 5 mm set-up uncertainty. Additionally, for the PBS plans a ± 3% proton range uncertainty was 
accounted for. Fractional dose re-calculations were performed using the planning computed tomography 
(CT) deformably registered to the daily cone-beam CT (CBCT) images. Fractional doses were 
accumulated rigidly. Planned and accumulated VMAT and PBS dose distributions were compared using 
dose-volume histogram (DVH) parameters. 
Results: Significant better sparing of the organs at risk with a maximum reduction in the mean dose of 
40% was achieved with PBS. Mean ITV DVH parameters differences between planned and CBCT 
accumulated dose distributions were smaller than 0.5% for both VMAT and PBS. However, the ITV 
coverage (V95% > 99%) was not reached for one patient for the accumulated VMAT dose distribution.  
Conclusions: For pediatric patients with abdominal tumors, improved dosimetric sparing was obtained 
with PBS compared to VMAT. In addition, PBS delivered by posterior-oblique irradiation fields 
demonstrated to be robust against anatomical inter-fraction changes. Compared to PBS, daily anatomical 
















Wilms’ tumor (WT) and neuroblastoma (NBL) belong to the most frequent abdominal tumors in 
pediatric patients [1,2].  Due to the use of a multimodality treatment comprising surgery, chemotherapy 
and radiotherapy, the survival rates for these patients have increased over the past few decades [3,4]. The 
sub-group of patients that receive radiotherapy is however at increased risk of developing toxicity to the 
normal tissue (NT).  
With the use of more advanced photon radiotherapy techniques, such as volumetric modulated arc 
therapy (VMAT), conformal dose gradients are delivered to complex target volumes enabling the 
reduction of the NT volume irradiated at tumor dose levels [5]. Nevertheless, low doses are still widely 
spread in the surrounding NT. With intensity-modulated proton therapy (IMPT) using a pencil beam 
scanning (PBS) delivery, as a result of the unique dose-deposition pattern characterized by the low 
entrance dose and rapid dose fall-off [6,7], there is hope to reduce the low dose bath and consequently the 
radiation-induced late effects [8]. In literature, clinical studies on PBS are sparse, patient cohorts are small 
and the follow-up is too short to evaluate long-term complications. However, publications assessing the 
dosimetric feasibility of treating pediatric abdominal tumors with PBS report a better NT sparing with this 
type of irradiation [9-12].  
During radiotherapy treatments in abdominal cancer, inter-fraction anatomical changes, such as 
patient diameter variations, due to weight loss/gain, and daily gastrointestinal gas volume differences, 
might occur. Due to the unpredictability of these changes over the treatment course and the difference 
between the depth-dose curves of photons and protons, the effect of inter-fraction uncertainties on the 
target and NT doses can be different between the two delivery techniques. In theory, proton dose 
distributions are more sensitive to uncertainties in computed tomography (CT) densities and changes in 
patient anatomy compared to photon dose distributions [13]. Robust treatment planning is currently used 
in proton radiotherapy to prevent that the target coverage is not maintained throughout the treatment by 
mitigating the effect of both range and set-up uncertainties [14-17]. 
To facilitate the choice between photons and protons to treat pediatric patients, a dosimetric 
comparison and an evaluation of the robustness of both delivery techniques should be performed. 
However, studies comparing the robustness of photon and proton delivery modalities against inter-
fraction anatomical changes for children have not been published yet. The goal of this study was to 
quantify for pediatric abdominal tumors: (1) the dosimetric differences in terms of dose sparing and (2) 
the dosimetric impact of daily anatomical changes based on cone-beam CT (CBCT) information between 
VMAT, used clinically at our department, and intensity-modulated PBS dose distributions. 
2. Materials and Methods 
 
2.1 Patient and imaging characteristics 
 
After institutional review board approval (WAG/mb/17/008865), data from 20 consecutive patients 
treated at our department between April 2015 and September 2017 were included in this study: 9 WT 
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patients (average: 3, range 1-8 years), undergoing flank irradiation after nephrectomy, and 11 NBL 
patients (average: 4, range 1-7 years) (supplementary material).  
For treatment preparation, patients were fixated in a vacuum mattress (Bluebag, Elekta, Stockholm, 
Sweden) in a supine position with the arms wide along the body. A 4-dimensional CT (4D-CT) was 
acquired for each patient in treatment position and using the same field of view (FOV): from the lungs 
until the lower abdomen. The 4D-CT images were obtained as a series of 10 phases using a 16-, 40-, or 
64- channel detector scanner (Brilliance, Philips Medical Systems, Best, The Netherlands). Scans with a 
current of 120 mA, with 90 kV, a pitch of 0.8, a gantry rotation speed of 0.7 s, a slice thickness of 3 mm 
corresponding to a CT dose index (CTDI) of 6 mGy were acquired. The planning-CT was obtained by 
taking the pixel-by-pixel average of the 10 phases of the 4D-CT. During treatment, daily CBCT images 
were acquired for all treatment fractions using the XVI 4.5.1 on-board CBCT imaging system (Elekta, 
Stockholm, Sweden). Scans with an arc of 200
o
 of 10 ms and 16 mA with 100 kV and an acquisition 
timeframe of 30 s, leading to four times less imaging dose than a standard adult pre-set (CTDI of 1 mGy), 
were taken. During treatment, each CBCT was registered to the planning-CT using the rigid registration 
algorithm available online on the XVI software (Elekta, Stockholm, Sweden)  [18,19]. 
 
2.2 Treatment planning characteristics 
 
The clinical target volume (CTV) was created by expanding the gross tumor volume (GTV) by 5 mm 
for the NBL patients and 10 mm for the WT patients. To account for the breathing motion, an internal 
target volume (ITV) was individualized for each patient and orthogonal direction. Breathing motion was 
assessed by measuring center of mass displacements of surgical clips, used as surrogates for the tumor 
bed boundaries, visible on the maximum expiration and inspiration phases of the 4D-CT image. ITV 
expansions were up to 1 mm in the left-right (LR) and anterior-posterior (AP) directions and up to 2 mm 
in the craniocaudal (CC) direction, depending on the patient [20]. All organs at risk (OARs) were 
contoured using the planning-CT. In addition, patient-specific safety margins were added to the OARs 
contours according to the individual motion measured on the 4D-CT image. OARs margins were up to 1 
mm in the LR and AP directions and up to 3 mm in the CC direction, depending on the organ and on the 
patient [20]. 
3D treatment plan optimization was performed in RayStation software (Raysearch, Stockholm, 
Sweden) using the planning-CT and using a collapsed cone engine for VMAT and a pencil beam 
algorithm for intensity-modulated PBS dose distributions [21]. According to the department clinical 
protocol, VMAT plans consisted of a full-arc. Given the posterior location of the tumor, 2 to 3 posterior 
irradiation fields were selected for the PBS plans. Number and direction of the proton beams (range [90º, 
240º]) were chosen individually per patient according to the tumor location and achievement of planning 
goals. To cover shallow targets, a range shifter of 40 mm was used. Additionally, a relative biological 
effectiveness (RBE) of 1.1 was included [21,22]. For PBS dose calculations, the Monte Carlo dose engine 
is known to be more accurate than the pencil beam algorithm [23]. Nevertheless, due to the posterior 
location of the target and the chosen beam configuration, an average uncertainty of 0.5% on the dose-
volume histogram (DVH) parameters was found between Monte Carlo and pencil beam optimized PBS 
5 
 
dose distributions. Given this negligible difference and the longer optimization time required by the 
Monte Carlo engine, PBS plans were computed using the pencil beam algorithm.    
The center of the ITV was defined as the isocenter for both modalities. The prescribed dose (PD) 
ranged from 14.4 to 36.0 Gy (from 8 to 20 fractions), depending on the patient (supplementary material). 
To reduce the risk of asymmetric skeletal growth, a homogeneous dose was aimed for the vertebra 
volume adjacent to the ITV for both modalities: V70-80% > 95-98%, depending on the patient [24].  
To assure a fair dosimetric comparison, both VMAT and PBS dose distributions were 3D ITV-based 
robustly optimized and evaluated accounting for several scenarios where patient set-up and range (only 
for PBS) uncertainties were simulated [21]. Set-up uncertainties were modeled by making translational 
shifts of the plan isocenter and range uncertainties by scaling the planning-CT density. A uniform 5 mm 
patient set-up and ± 3% range uncertainties were accounted for [13,25]. During 3D robust plan 
optimization, robustness against these uncertainties was attained using a minimax optimization method 
[14,21]. Plans were optimized accounting for different dose scenarios using the selected set-up (5 mm in 6 
directions plus nominal plan) and range (± 3% plus nominal plan, only for PBS) uncertainties. In total, 7 
and 21 dose scenarios were calculated during the VMAT and PBS plan optimization, respectively. For the 
3D robust plan evaluation, different dose scenarios were computed using the same magnitude of the set-
up (5 mm in 26 fixed directions) and range (± 3%, only for PBS) uncertainties. In total, 26 and 52 dose 
scenarios were calculated for the VMAT and PBS plans, respectively. The information from all scenarios 
per technique was combined in a voxel-wise minimum evaluation dose (Vwmin) by calculating the 
minimum dose per voxel in all scenarios. Plans were considered clinically robust if 98% of the ITV 
received at least 95% of the PD (V95% > 98%) in the Vwmin  [26]. 
As a result of the proton finite range and stopping power sensitivity to electron density variations, the 
robustness of the planned PBS dose distributions may be compromised by small deviations occurring 
during treatment delivery, such as (1) patient anatomy changes due to breathing motion, (2) inter-play 
effects and (3) machine errors [27]. Therefore, to assure that for this patient group a 3D ITV-based robust 
optimization is sufficient to cover these disturbing effects (1-3), a 4D robustness evaluation method 
(4DREM) was used to evaluate the PBS dose distribution of the patient denoting the largest target 
breathing motion (2 mm in the CC direction) [28]. Disturbing effects were considered by calculating sub-
plan doses, based on treatment-plan specific delivery-machine log files, on all 10 phases of the 4D-CT 
image [28]. Phase-specific dose contributions were accumulated on the expiration phase using 
ANACONDA (Anatomically Constrained Deformation Algorithm) algorithm available in RayStation 
software [21]. Additionally, for each sub-plan, set-up and range uncertainties were incorporated by 
calculating dose scenarios accounting for 5 mm isocenter shifts in 14 directions and planning-CT density 
perturbations of ± 3%. PBS plan robustness was evaluated by calculating a 4D accumulated Vwmin (4D 
Vwamin) obtained from the computed phase-specific dose scenarios. Robustness was confirmed if 98% of 








2.3 Fractional dose calculation and  accumulation 
 
Fractional dose re-calculations were performed using the daily CBCT images. Despite CBCT is 
commonly employed for patient position verification during treatment, the imaging quality is inferior 
compared to CT resulting in incorrect Hounsfield units (HUs) for dose calculations [29-31]. For the 
estimation of the HUs from the CBCTs, the planning-CT was deformably registered to each CBCT using 
Evolution [32]. This algorithm was previously validated for CT-CBCT registrations for kidney and lung 
cancer patients [33]. The performance of the registration algorithm was evaluated by visual inspection of 
tissue landmarks (e.g surgical clips). On the deformed CTs (dCTs), the gas volumes from the planning-
CT were filled with a water equivalent density (0 HU) and the gas volumes from the CBCTs were rigidly 
copied for dose calculation purposes. Fractional doses were re-calculated on the dCTs and accumulated 
rigidly on the planning-CT. A rigid dose accumulation was chosen due to the limited soft-tissue contrast 
seen on the CBCTs (Figure 1). As CBCT images were acquired with less imaging dose than a standard 
adult protocol (section 2.1), an accurate estimation of the daily deformations cannot be guaranteed for all 
structures. Thus, the clinical ITV and OARs, delineated on the planning-CT, were used for the planned 





The changes in patient diameter and in gastrointestinal gas volume on the planning-CT and CBCTs 
were calculated for each patient. Gastrointestinal gas pockets were delineated within the available CBCT 
FOV. Variations in patient diameter were assessed by computing the difference of the distance in the AP 
direction of the ITV center of mass to the patient’s surface between the planning-CT and the CBCT 
images.  
 
2.4.2 Dosimetry  
 
Two separate evaluations were performed: (1) comparison between VMAT and PBS planned dose 
distributions in terms of ITV robustness and dose sparing and (2) comparison between planned and CBCT 
accumulated VMAT and PBS dose distributions in terms of ITV robustness, OARs and NT doses.  
For both (1) and (2), clinical DVH parameters were evaluated. For the ITV, the D98%, D50%, and D2% 
were computed. In addition, the V95% was calculated in the Vwmin and in the CBCT accumulated Vwmin 
(CBCT Vwamin) to evaluate the robustness of planned (1) and accumulated (2) dose distributions, 
respectively. CBCT Vwamin was obtained using a 1 mm set-up uncertainty (in 26 fixed directions), to 
simulate residual treatment errors, and a ± 3% range uncertainty (only for PBS). For the OARs, mean 
dose (Dmean), D50% and D2% were computed.  For the NT (defined as the body minus the ITV), Dmean, V2Gy 







In total, 224 CBCTs were evaluated. Patient diameter variations between the planning-CT and 
CBCTs were on average 0.5 ± 0.4 cm (range [-1.2; 2.0] cm). The volume of gastrointestinal gas as seen 
on the CBCT images showed large differences compared to the planning-CT: average 99.4 ± 126.9 ml 




ITV coverage was fulfilled in the planned VMAT and PBS dose distributions. Mean V95% in the 
Vwmin was 98.7% ± 0.5% (range [98.2%; 99.8%]) and 98.8% ± 0.6% (range [98.1%; 99.6%]) for VMAT 
and PBS dose distributions, respectively. For the patient denoting the largest breathing motion, the V95% 
of the CTV was 99.8% in the 4D Vwamin. Significant better sparing of the OARs and NT was achieved 
with PBS when compared to VMAT for all patients (Table 1, Figure 2). The average reduction in the 
Dmean was 12.9 ± 8.0% (range [3.4%; 33.1%]) for the contralateral kidney, 8.1 ± 4.5% (range [2.0%; 
15.7%]) for the ipsilateral kidney, 22.8 ± 7.4% (range [5.5%; 34.8%]) for the liver, 13.4 ± 7.7% (range 
[1.6%; 28.9%]) for the spleen, 17.4 ± 10.5% (range [3.8%; 39.5%]) for the pancreas and 8.0 ± 2.6% 
(range [3.7%; 13.9%]) for the NT.  
Significant differences between the planned and CBCT accumulated dose distributions were only 
found for the ITV on the VMAT plans (Table 2). For the accumulated VMAT dose distributions, the ITV 
coverage was not met for one patient due to the large variation of gas volumes between the planning-CT 
and the CBCT images (Figure 3). Smaller dose differences on the ITV were found between planned and 
accumulated PBS dose distributions (Table 2, Figure 3). Mean V95% in the CBCT Vwamin was 99.6% ± 
0.8% (range [96.8%; 100%]) and 99.8% ± 0.3% (range [99.1%; 100%]) for VMAT and PBS dose 
distributions, respectively. For the OARs, mean differences between planned and CBCT accumulated 
dose distributions were below 2% for VMAT and below 0.6% for PBS. Moreover, larger individual 
differences were found for VMAT (range [-11.3%; 9.6%]) compared to PBS (range [-5.3%; 5.2%]) dose 




In the present study, dosimetric differences between 3D ITV-based robustly optimized VMAT and 
intensity-modulated PBS dose distributions were quantified in 20 pediatric patients with abdominal 
cancer. Moreover, the robustness of VMAT and PBS dose distributions against inter-fraction anatomical 
changes (<2cm, <455ml), visualized on daily CBCT images,  was investigated for the same patient group. 
Results demonstrate a significant dosimetric sparing of the OARs and NT without compromising the 
target dose with PBS for all patients. Furthermore, PBS delivered by posterior-oblique irradiation fields 




In literature, the dosimetric sparing with PBS was already investigated for both WT and NBL 
patients against conventional radiotherapy using two opposing fields [9,12], 3D conformal radiotherapy 
[11] and intensity-modulated radiation therapy (IMRT) [9,10]. Nevertheless, none of these studies 
compared PBS against VMAT. In addition, none of them used robust optimization and evaluation to 
account for the effect of both set-up and range uncertainties on the PBS dose distributions limiting the 
generality of the comparison between approaches. In proton therapy, uncertainties in CT densities and 
patient anatomy can generate severe effects on the delivered dose as proton path length changes result in 
displacements of the Bragg peak dose fall-off [34,35]. Consequently, a PTV-based plan optimization is 
not accurate enough for proton therapy [35,36]. In the present study, ITV-based robustly optimized 
VMAT plans were chosen for the comparison with PBS to mitigate biases related to the use of different 
optimization methods. Being aware that photon planning is commonly done using a PTV approach, 
differences between PTV-based and ITV-based robustly optimized VMAT dose distributions were 
calculated (supplementary material). No significant deviations were found for the majority of the DVH 
parameters. In addition, a realistic choice of set-up and range (only for PBS) uncertainties was aimed 
during the robust optimization and evaluation [13,25]. However, it can still be argued if the chosen 
uncertainties are too large given the available online image guidance and verification techniques. In 
previous studies [20,37], we estimated the target safety margin to use in a CBCT-guided workflow for a 
group of 15 WT patients. When accounting for the treatment chain geometric accuracy, patient set-up and 
inter-fraction motion uncertainties, a target safety margin of 5 mm in all orthogonal directions was 
calculated [37]. For this reason, a 5 mm set-up uncertainty plus an ITV margin to account for the 
breathing motion were used in this study. Nevertheless, range uncertainties might be further mitigated by 
the use of dual-energy CT [38] or proton CT [39].  
In literature, 4D robustly optimized and evaluated PBS dose distributions are reported to be more 
robust and interplay-effect-resistant for moving targets than 3D robustly optimized dose distributions 
[40]. Since the use of 4D robust optimization and evaluation implies more manual work and optimization 
time, in the present work a 3D robust optimization and evaluation of the PBS dose distributions was 
performed. In addition, a 4D evaluation of the 3D robustly optimized PBS dose distribution for the patient 
denoting the largest breathing motion was done. For this patient, the target criterion (V95%>98% in the 
Vwmin) was met for both 3D and 4D evaluation methods (98.9% vs. 99.8%). Due to the target posterior 
location, the beam configuration chosen and the small magnitude of the breathing motion seen for this 
patient group [20], using 3D robustly optimized and evaluated PBS dose distributions is considered 
clinically suitable. Moreover, plan robustness evaluation was performed using a Vwmin and not a worst-
case dose as previously reported in literature [16,36]. Vwmin was chosen as a better agreement between the 
PTV criteria for photon plans and the target DVH criteria for PBS was denoted in comparison to the 
worst-case evaluation dose [26].  
In this study, VMAT and PBS dose distributions robustness against inter-fraction anatomical 
changes was assessed using daily CBCT images. Due to the existence of possible image artifacts and 
inaccurate HUs, CBCT images are of limited value for direct dose calculations. Several methods to enable 
CBCT dose calculations have already been published in literature [31,41-43]. In the present work, the 
planning-CT was deformably registered to the CBCTs to calculate the fractional doses. Thus, two 
potential limitations of this approach are (1) the rigid accumulation of fractional doses and (2) the manual 
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adaptation of daily gastrointestinal gas volume variations. For a deformable dose accumulation, a voxel-
by-voxel accuracy is required [41] which cannot be ensured due to the poor CBCT image quality seen 
(Figure 1). While using a rigid dose accumulation, daily anatomical deformations were neglected. 
Nevertheless, the largest inter-fraction anatomical changes, such as patient diameter and gastrointestinal 
gas volume variations, were accounted for. The manual adaptation of the gas volumes was sufficient for 
the purpose of this study but can represent a limitation for daily online re-planning. Due to the 
unpredictability of gastrointestinal gas volume changes, for the calculation of the fractional doses in 
abdominal cancer patients using a CBCT scatter correction approach as suggested by [43] or fast deep 
learning methods [44,45] might be considered better options for an online re-planning workflow. 
Nevertheless, these methods either require (1) storing of vendor specific CBCT projections [43], which is 
a disadvantage when needing to use other on-board imaging systems, or (2) large amounts of imaging 
data [44,45], which is a limitation for children due to the large variability in age, height and weight in 
pediatric cohorts.  
The results of this study show that the ITV coverage was reduced in the CBCT accumulated VMAT 
dose distribution compared to the planned dose for one patient. Smaller ITV and OARs dose differences 
were seen for PBS as a result of the selected beam configuration/angles. With the use of patient-specific 
posterior-oblique irradiation fields, uncertainties related to the variation of gastrointestinal gas volumes 
during treatment can be avoided as the proton beams stop before reaching the anterior part of the 
abdomen. Clinically, the VMAT plans are optimized using a full-arc as a requirement to achieve both an 
acceptable target coverage and a homogeneous dose in the vertebra [24]. Thus, planning strategies such as 
performing a density override of the gastrointestinal gas pockets on the planning-CT or using online daily 
re-planning might be necessary to reduce discrepancies between planned and delivered photon doses. In 
future studies investigating the robustness of both photon and proton radiotherapy plans, imaging data 
with more appropriate image quality should be used to better quantify the target and OARs fractional 
doses. Furthermore, the plan robustness evaluation should be included in trials to select patients that 
benefit from proton therapy. From a dosimetric point-of-view to treat children with WT or NBL, PBS 
showed to be more favorable, regarding both dose sparing and robustness against inter-fraction 
anatomical changes, compared to VMAT. Nevertheless, long-term follow-up of a large pediatric cohort is 
mandatory to estimate the real clinical benefit of treating children with PBS. In addition, a comprehensive 
dosimetric assessment of the available radiotherapy modalities is essential to take advantage of more 
recent techniques. In comparison with PBS, MRI-guided treatments are also showing to be promising for 
pediatric patients. With MRI-guided systems [46], the use of decreased safety margins due to the better 
visualization of the target could be achieved allowing for real-time adaptive regimes without extra patient 
radiation burden [47]. In a previous study [37], we have quantified the dosimetric impact when using 
MRI-guided IMRT (IMRTMRI) compared to the clinical VMAT workflow to treat WT patients (n=15). 
When using a PTV margin of 1 mm for the IMRTMRI (simulating a best-case scenario), the calculated 
Dmean was 18% in the kidneys, 30% in the liver, 32% in the spleen and 68% in the pancreas. In the present 
study, for the same patient category (WT, n=9) when using robustly optimized intensity-modulated PBS 
dose distributions (5mm, 3%), the computed Dmean was 15% in the kidneys, 10% in the liver, 32% in the 
spleen and 53% in the pancreas. Consequently for this patient category, PBS using current clinical 
robustness settings is shown to be more dosimetrically favorable compared to the best-case scenario of 
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IMRTMRI. In the future, further dosimetric sparing might be expected if using MRI-guided PBS (PBSMRI). 
This approach is not clinically available yet, however research has been going on to prove the feasibility 
of MRI-guided proton systems and the corresponding treatment workflow [48]. Future work will include 
evaluating the potential dosimetric benefit with PBSMRI for pediatric patients with abdominal tumors. 
This study provides substantial dosimetric information to help assessing the optimal referral patterns 
for pediatric patients with abdominal tumors. Whether the reported dosimetric gain and robustness against 
inter-fraction anatomical changes of PBS dose distributions is translated into any clinical benefit for this 
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Figure 1. Schematic representation of the workflow used in this study. For the image acquisition (1), a 
planning-CT and daily CBCTs were acquired for each patient. CBCT images were obtained online for all 
treatment fractions and rigidly registered to the planning-CT. For the fractional dose re-calculations, the 
planning-CT was deformably registered to the CBCT images (2). Fractional doses were re-calculated on 



















Figure 3. VMAT (a) and PBS (b) planned and CBCT accumulated dose distributions for the patient 
failing the ITV coverage in the accumulated VMAT dose distribution. Dose distributions are overlaid on 
the planning-CT. The 95% isodose is shown in red and the ITV in white. ΔD denotes the dose difference 
between planned and CBCT accumulated dose distributions in a -0.5 (blue, planned < accumulated dose) 














Table 1. DVH parameters (%) comparison of VMAT and PBS dose distributions, with p<0.05 (Wilcoxon 
signed-rank test) considered significant (in bold). ∆D denotes the difference between VMAT and PBS 
dose distributions. Values are presented as a percentage of the respective PD. Abbreviations: SD= 
standard deviation. 
Structures Parameter 
VMAT (%) PBS (%) ∆D (VMAT-PBS) (%) 
mean ± SD  mean ± SD  mean ± SD  range  p 
ITV 
D98% 98.1 ± 0.5 98.1 ± 0.5 0.0 ± 0.8 [-1.2 ; 1.5] 1.0 
D50% 100.2 ± 0.1 100.4 ± 0.2 -0.2 ± 0.2 [-0.6 ; 0.4] 1.6E-4 
D2% 102.9 ± 1.0 104.0 ± 0.9 -1.2 ± 1.1 [-3.5; 0.9] 1.0E-3  
Kidney 
contralateral 
D50% 23.8 ± 10.5 9.8 ± 10.5 14.1 ± 9.1 [0.9 ; 37.6] 2.6E-4 
D2% 70.8 ± 22.6 62.2 ± 26.0 8.6 ± 9.4 [-3.3 ; 35.5] 0.3 
Kidney 
ipsilateral 
D50% 57.7 ± 26.2 48.5 ± 29.5 9.2 ± 5.2 [0.2 ; 17.6] 0.4 
D2% 95.2 ± 17.3 94.2 ± 19.0 0.9 ± 2.1 [-1.5 ; 5.4] 0.8 
Liver 
D50% 26.4 ± 13.1 0.3 ± 0.9 26.1 ± 12.7 [1.0 ; 49.7] 7.6E-8 
D2% 81.6 ± 16.9 67.3 ± 28.5 14.4 ± 13.6 [-0.7 ; 38.8] 0.2 
Spleen 
D50% 32.3 ± 32.8 17.7 ± 34.1 14.6 ± 10.5 [-1.3 ; 35.4] 1.1E-3 
D2% 65.2 ± 37.0 58.1 ± 43.8 7.2 ± 9.5 [-3.0 ; 25.1] 0.7 
Pancreas 
D50% 83.4 ± 22.8 66.8 ± 31.6 16.6 ± 17.1 [-0.8 ; 55.6] 4.4E-2 
D2% 98.7 ± 10.0 96.7 ± 21.6 1.9 ± 11.7 [-4.0 ; 51.1] 0.2 
NT 
V2Gy 34.0 ± 8.8 14.2 ± 5.0 19.8 ± 5.2 [12.7; 30.2] 1.4E-7 




















Table 2. Dose differences (∆D) between planned and CBCT accumulated dose distributions for VMAT 
and PBS, with p<0.05 (Wilcoxon signed-rank test) considered significant (in bold). Values are presented 
as a percentage of the respective PD. If ΔD>0 the planned dose is higher than the accumulated dose and 
ΔD<0 otherwise. Abbreviations: SD= standard deviation. 
Structures Parameter 
∆D (VMAT, planned-accumulated) (%) ∆D (PBS, planned-accumulated) (%) 
mean ± SD  range  p mean ± SD range  p 
ITV 
D98% 0.5 ± 0.9 [-1.9 ; 2.6] 3.4E-2 0.2 ± 0.5 [-0.3 ; 0.7] 0.7 
D50% 0.1 ± 0.8 [-2.4 ; 1.3] 0.2 0.1 ± 0.1 [-0.1 ; 0.3] 0.2 
D2% -0.2 ± 0.9 [-2.8 ; 1.3] 0.6 -0.1 ± 0.6 [-1.7 ; 0.5] 1.0 
Kidney 
contralateral 
D50% -0.2 ± 1.3 [-3.7 ; 2.6] 1.0 -0.2 ± 0.4 [-1.2 ; 0.4] 0.9 
D2% -0.8 ± 3.5 [-9.4 ; 5.5] 0.9 0.0 ± 1.3 [-2.4 ; 4.2] 1.0 
Kidney 
ipsilateral 
D50% 1.9 ± 3.6 [-1.7; 9.6] 0.9 -0.1 ± 0.8 [-1.7 ; 1.2] 1.0 
D2% 0.0 ± 1.1 [-2.7 ; 1.9] 1.0 0.2 ± 0.6 [-0.2 ; 1.9] 0.8 
Liver 
D50% 0.4 ± 0.8 [-0.1 ; 2.6] 0.8 -0.2 ± 0.7 [-3.2 ; 0.1] 0.7 
D2% 0.6 ± 1.6 [-2.5 ; 4.8] 0.9 0.5 ± 2.5 [-4.8 ; 5.2] 1.0 
Spleen 
D50% 0.1 ± 0.8 [-1.7 ; 2.1] 1.0 0.2 ± 0.8 [-0.5 ; 3.4] 0.9 
D2% -0.6 ± 3.0 [-11.3 ; 3.3] 0.8 0.0 ± 1.0 [-3.4 ; 1.6] 0.9 
Pancreas 
D50% 0.6 ± 1.5 [-1.9 ; 3.5] 0.9 0.6 ± 2.6 [-5.3 ; 4.7] 1.0 
D2% 0.1 ± 1.2 [-2.4 ; 2.3] 0.9 0.1 ± 1.0 [-2.2 ; 2.2] 0.6 
NT 
V2Gy 0.7 ± 0.8 [-0.1 ; 3.0] 0.7 -0.1 ± 0.4 [-0.9 ; 0.9] 0.9 
V95% 0.1 ± 0.3 [-0.6 ; 0.8] 1.0 0.1 ± 0.1 [-0.1 ; 0.2] 0.8 
 
